-DOCSTART- -X- O
Previous -X- _ O
studies -X- _ O
of -X- _ O
HIV-1 -X- _ B-Intervention
p55Gag -X- _ I-Intervention
immunization -X- _ I-Intervention
of -X- _ O
mice -X- _ O
have -X- _ O
demonstrated -X- _ O
the -X- _ O
usefulness -X- _ O
of -X- _ O
targeting -X- _ O
antigens -X- _ O
to -X- _ O
the -X- _ O
cellular -X- _ O
compartment -X- _ O
containing -X- _ O
the -X- _ O
major -X- _ O
histocompatibility -X- _ O
complex -X- _ O
type -X- _ O
II -X- _ O
( -X- _ O
MHC -X- _ O
II -X- _ O
) -X- _ O
complex -X- _ O
molecules -X- _ O
by -X- _ O
use -X- _ O
of -X- _ O
a -X- _ O
DNA -X- _ B-Intervention
antigen -X- _ I-Intervention
formulation -X- _ I-Intervention
encoding -X- _ I-Intervention
Gag -X- _ I-Intervention
as -X- _ I-Intervention
a -X- _ I-Intervention
chimera -X- _ I-Intervention
with -X- _ O
the -X- _ O
mouse -X- _ O
lysosome-associated -X- _ O
membrane -X- _ O
protein -X- _ O
( -X- _ O
mLAMP -X- _ O
/ -X- _ O
gag -X- _ O
) -X- _ O
. -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
analyzed -X- _ O
the -X- _ O
magnitude -X- _ O
and -X- _ O
breadth -X- _ O
of -X- _ O
Gag-specific -X- _ B-Outcome
T-lymphocyte -X- _ I-Outcome
and -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
elicited -X- _ O
in -X- _ O
Rhesus -X- _ B-Patient
macaques -X- _ I-Patient
after -X- _ O
immunization -X- _ B-Intervention
with -X- _ I-Intervention
DNA -X- _ I-Intervention
encoding -X- _ I-Intervention
a -X- _ I-Intervention
human -X- _ I-Intervention
LAMP -X- _ I-Intervention
/ -X- _ I-Intervention
gag -X- _ I-Intervention
( -X- _ I-Intervention
hLAMP -X- _ I-Intervention
/ -X- _ I-Intervention
gag -X- _ I-Intervention
) -X- _ I-Intervention
chimera. -X- _ I-Intervention
ELISPOT -X- _ O
analyses -X- _ O
indicated -X- _ O
that -X- _ O
the -X- _ O
average -X- _ O
Gag-specific -X- _ B-Outcome
IFN-γ -X- _ I-Outcome
response -X- _ I-Outcome
elicited -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
hLAMP -X- _ I-Outcome
/ -X- _ I-Outcome
gag -X- _ I-Outcome
chimera -X- _ I-Outcome
was -X- _ I-Outcome
detectable -X- _ I-Outcome
after -X- _ O
only -X- _ B-Intervention
two -X- _ I-Intervention
or -X- _ I-Intervention
three -X- _ I-Intervention
naked -X- _ I-Intervention
DNA -X- _ I-Intervention
immunizations -X- _ I-Intervention
in -X- _ O
all -X- _ O
five -X- _ B-Patient
immunized -X- _ I-Patient
macaques -X- _ I-Patient
and -X- _ O
reached -X- _ B-Outcome
an -X- _ I-Outcome
average -X- _ I-Outcome
of -X- _ I-Outcome
1000 -X- _ I-Outcome
spot-forming -X- _ I-Outcome
cells -X- _ I-Outcome
( -X- _ I-Outcome
SFC -X- _ I-Outcome
) -X- _ I-Outcome
/ -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
6 -X- _ I-Outcome
) -X- _ I-Outcome
PBMCs. -X- _ I-Outcome
High -X- _ I-Outcome
IFN-γ -X- _ I-Outcome
ELISPOT -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ B-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
-depleted -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
that -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T-cells -X- _ I-Outcome
play -X- _ I-Outcome
a -X- _ I-Outcome
major -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
responses. -X- _ I-Outcome
The -X- _ O
T-cell -X- _ B-Outcome
responses -X- _ I-Outcome
of -X- _ O
four -X- _ B-Patient
of -X- _ I-Patient
the -X- _ I-Patient
macaques -X- _ I-Patient
were -X- _ O
also -X- _ O
tested -X- _ O
by -X- _ O
use -X- _ O
of -X- _ O
ELISPOT -X- _ O
to -X- _ O
12 -X- _ O
overlapping -X- _ O
15-amino -X- _ O
acids -X- _ O
( -X- _ O
aa -X- _ O
) -X- _ O
peptide -X- _ O
pools -X- _ O
containing -X- _ O
ten -X- _ O
peptides -X- _ O
each -X- _ O
, -X- _ O
encompassing -X- _ O
the -X- _ O
complete -X- _ O
Gag -X- _ O
protein -X- _ O
sequence. -X- _ O
The -X- _ O
two -X- _ B-Patient
Mamu -X- _ I-Patient
08 -X- _ I-Patient
immunized -X- _ I-Patient
macaques -X- _ I-Patient
responded -X- _ B-Outcome
to -X- _ I-Outcome
eight -X- _ I-Outcome
and -X- _ I-Outcome
twelve -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
pools -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
Mamu -X- _ I-Outcome
B01 -X- _ I-Outcome
to -X- _ I-Outcome
six -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
other -X- _ I-Outcome
macaque -X- _ I-Outcome
to -X- _ I-Outcome
five -X- _ I-Outcome
pools -X- _ I-Outcome
indicating -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
hLAMP -X- _ I-Outcome
/ -X- _ I-Outcome
gag -X- _ I-Outcome
DNA -X- _ I-Outcome
antigen -X- _ I-Outcome
formulation -X- _ I-Outcome
elicits -X- _ I-Outcome
a -X- _ I-Outcome
broad -X- _ I-Outcome
T-cell -X- _ I-Outcome
response -X- _ I-Outcome
against -X- _ I-Outcome
Gag. -X- _ I-Outcome
Additionally -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
strong -X- _ I-Outcome
HIV-1-specific -X- _ I-Outcome
IgG -X- _ I-Outcome
response. -X- _ I-Outcome
The -X- _ I-Outcome
IgG -X- _ I-Outcome
antibody -X- _ I-Outcome
titers -X- _ I-Outcome
increased -X- _ I-Outcome
after -X- _ I-Outcome
each -X- _ I-Outcome
DNA -X- _ I-Outcome
injection -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
a -X- _ I-Outcome
strong -X- _ I-Outcome
amnestic -X- _ I-Outcome
B-cell -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
were -X- _ I-Outcome
highly -X- _ I-Outcome
elevated -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
the -X- _ I-Outcome
macaques -X- _ I-Outcome
after -X- _ I-Outcome
three -X- _ I-Outcome
immunizations. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
serum -X- _ I-Outcome
of -X- _ I-Outcome
each -X- _ I-Outcome
macaque -X- _ I-Outcome
recognized -X- _ I-Outcome
13 -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
49 -X- _ I-Outcome
peptides -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
20-aa -X- _ I-Outcome
peptide -X- _ I-Outcome
library -X- _ I-Outcome
covering -X- _ I-Outcome
the -X- _ I-Outcome
complete -X- _ I-Outcome
Gag -X- _ I-Outcome
amino -X- _ I-Outcome
acid -X- _ I-Outcome
sequence. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
HIV-1-specific -X- _ I-Outcome
IgA -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
present -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
plasma -X- _ I-Outcome
and -X- _ I-Outcome
external -X- _ I-Outcome
secretions -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
nasal -X- _ I-Outcome
washes. -X- _ I-Outcome
These -X- _ I-Outcome
data -X- _ I-Outcome
support -X- _ I-Outcome
the -X- _ I-Outcome
findings -X- _ I-Outcome
of -X- _ I-Outcome
increased -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
of -X- _ I-Outcome
genetic -X- _ I-Outcome
vaccines -X- _ I-Outcome
encoded -X- _ I-Outcome
as -X- _ I-Outcome
LAMP -X- _ I-Outcome
chimeras -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
the -X- _ I-Outcome
response -X- _ I-Outcome
to -X- _ I-Outcome
DNA -X- _ I-Outcome
vaccines -X- _ I-Outcome
by -X- _ I-Outcome
non-human -X- _ I-Outcome
primates -X- _ I-Outcome
. -X- _ O

